171 results about "Mannoglucan" patented technology

The invention discloses a high temperature resistant beta-mannase mutant and a preparation method thereof, wild type beta-mannase comes from Coprinus cinerea, the wild type beta-mannase is modified by using a directed evolution means to obtain the high temperature resistant beta-mannase mutant, and the mutation of the mutant comprises at least one of N381K, R123Y and M439L. The beta-mannase mutant has good thermal stability under the alkaline condition and longer heating time, the enzyme activity of the mutant is improved by 107.0% compared with that of an original enzyme when the beta-mannase mutant is treated for 2 h at the high temperature of 90 DEG C in a buffer solution with the pH value of 10, the capacity of catalyzing beta-mannase hydrolysis by the enzyme mutant is obviously improved, and the beta-mannase mutant has wide application prospects.

The invention relates to the technical field of dendrobium officinale polysaccharide processing and active ingredient function improvement, in particular to a preparation method of a dendrobium officinale polysaccharide fragment. According to the specific technical scheme, the method comprises the following steps: adding mannase with enzyme activity of 0.7-1U into a dendrobium officinale polysaccharide solution, and stirring for 0.5-1.5 hours; and adding absolute ethyl alcohol until the concentration is 65-75%, centrifuging to remove supernate, collecting precipitate, adding water to redissolve, concentrating, and freeze-drying to obtain the dendrobium officinale polysaccharide fragment. The dendrobium officinale polysaccharide with higher immunoregulatory activity can be conveniently and rapidly obtained in an enzymolysis mode.

The invention relates to the technical field of functional food, in particular to immune regulation type prebiotic syrup with synergy of galactomannan. The active components of the composite solid beverage are prepared from the following raw materials in percentage by weight: 20%-35% of fructo-oligosaccharide, 10%-18% of galactooligosaccharide, 8%-15% of stachyose, 3%-7% of xylooligosaccharide, 5%-12% of lactitol, 5%-10% of galactomannan, 2%-5% of yeast beta-glucan and 1%-3% of N-acetylglucosamine. The composition further comprises 4-8% of inulin and 3-6% of resistant dextrin as a matrix filling and slow-release carrier, and the sum of the weight percentages of all the active ingredients and the carrier is 100%. By remodeling intestinal microecology and inhibiting inflammation pathways, the intestinal inflammation state can be remarkably improved, expression of intestinal mucosa tight junction protein is promoted, and an innovative solution is provided for people suffering from chronic bowel diseases and immune imbalance.

The invention discloses a method for degumming ramie by using biological enzymes, and belongs to the technical field of ramie processing. The method provided by the invention comprises the steps of degumming by using a composite enzymatic hydrolyzate of pectinase, mannanase and xylanase, alkali boiling, cleaning, bleaching and acid washing, cleaning, dehydration and the like. The weight loss rate of ramie treated by the method can reach about 47.8%, compared with the traditional chemical method, such as the weight loss rate of about 18% for alkali boiling using NaOH, the method not only significantly improves the degumming efficiency and improves the fiber quality, but also reduces the production cost and environmental pollution, and has significant technical advantages and economic benefits.

The present invention relates to a low-nucleic acid yeast protein and a preparation method thereof, and belongs to the field of microbial application technology. The present invention creatively adds xylitol and sodium glycine to a fresh yeast dispersion prepared with deionized water as a dispersion medium, then performs a denucleic acid treatment under alkaline and high temperature conditions, obtains a heavy phase after subsequent centrifugation, and then continues to use deionized water as a dispersion medium to prepare a heavy phase dispersion, and successively adds two different enzymes, namely glucanase and β-mannanase, for enzymatic hydrolysis, thereby further reducing the nucleic acid content and increasing the protein content, thereby preparing a low-nucleic acid yeast protein, wherein the nucleic acid content can be less than 1.5wt%, and the protein content can be greater than 75wt%, effectively expanding the use field of yeast protein.

The present invention relates to mannanase variants with improved stability. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.

The invention belongs to the technical field of food processing, and particularly relates to a product rich in soluble yeast dietary fibers and a preparation method and application thereof. Wherein in terms of dry matter mass of the product containing the soluble yeast dietary fiber, the product containing the soluble yeast dietary fiber comprises the following components in percentage by mass: more than 40% of soluble yeast dietary fiber, less than 0.5% of fat, more than 20% of yeast beta-glucan and more than 20% of mannan. The product containing the soluble yeast dietary fibers prepared by the preparation method disclosed by the invention contains the soluble dietary fibers with higher content, the solubility is obviously improved, the mouth feel is improved to a certain extent, and the product contains lower fat content and is more beneficial to storage; and meanwhile, the product is rich in beta-glucan and mannan, so that the product has a wide application prospect.

The invention relates to the technical field of microorganism application, in particular to low-nucleic-acid yeast protein as well as a preparation method and application thereof. The preparation method of the low-nucleic-acid yeast protein comprises the following steps: (1) carrying out inactivation treatment on high-protein yeast; (2) carrying out enzymolysis on the inactivated yeast by adopting neutral protease, glucanase, mannase and first nuclease, and after enzyme deactivation, separating and taking a heavy phase to obtain crude yeast protein; (3) performing high-pressure homogenization treatment on the crude yeast protein; and (4) carrying out enzymolysis on the crude yeast protein subjected to high-pressure homogenization treatment by adopting second nuclease and lipase, and after enzyme deactivation, separating and taking a heavy phase to obtain the low-nucleic-acid yeast protein. The yeast protein with the nucleic acid content of 1.0% or below is obtained by taking the high-protein yeast as a raw material through inactivation, compound enzyme enzymolysis, high-pressure homogenization treatment and secondary enzymolysis, is neutral and pure in taste, and can be widely applied to the fields of nutrition, health and food such as protein supplementation and protein substitution.

To provide konjak-like food with high protein content, while utilizing the advantages of konjac, which has a unique texture and a low caloric value.SOLUTION: A liquid mixture contains 0.3 w / w% or more and 2.5 w / w% or less of glucomannan, 0.2 w / w% or more and 2.5 w / w% or less of alginic acid and / or a salt thereof, and 3.0 w / w% or more and 12.0 w / w% or less of vegetable protein, optionally containing 0.1 w / w% or more and 1.5 w / w% or less of xanthan gum, and substantially free of gluten. The liquid mixture is discharged into an aqueous solution containing divalent cations to produce a gel-like product.SELECTED DRAWING: None

The invention discloses a phosphoric acid compound capable of resisting intestinal bacterial adhesion as well as a preparation method and application of the phosphoric acid compound, and belongs to the technical field of foods and medicines. The phosphoric acid compound is prepared from an amino-rich compound, a solution containing a phosphate compound with the mass concentration being 3% or above, a solution containing a zinc compound with the mass concentration being 3% or above, glucomannan, an alkaline solution and water. The phosphoric acid compound can effectively inhibit the adhesion of bacteria to intestinal mucosa, can control the probability of intestinal bacteria invasion, reduce the occurrence probability of intestinal leakage, control chronic inflammation in the body, can solve the intestinal health problem caused by the adhesion of intestinal bacteria, and plays an important role. In order to ensure the safety of the product and not introduce reagents and substances harmful to health, the used preparation process and production process are simple and easy to industrially amplify, harmful substances are prevented from being generated in the production process, the operation is easy, and large-scale production can be realized.

The present invention relates to the technical field of clinical medicine immunodetection, and discloses an aspergillus galactomannan detection kit and a preparation method thereof, the aspergillus galactomannan detection kit comprises a test paper card and a sample treatment liquid, the test paper card comprises a bottom plate, and a sample pad, a labeling pad A, a labeling pad B, a nitrocellulose membrane and water absorption paper which are sequentially arranged from a sample adding end on the surface of the bottom plate, the labeling pad A is provided with a quantum dot-biotin labeled aspergillus galactomannan monoclonal antibody, the labeling pad B is provided with microspheres coupled with the aspergillus galactomannan monoclonal antibody, and the nitrocellulose membrane is coated with streptavidin and goat anti-mouse IgG. According to the invention, the defect of low sensitivity can be overcome.

The application discloses a high-stability immobilized mannanase and a preparation method and application thereof, and belongs to the technical field of enzyme immobilization. The preparation method uses PAMAM modified SBA-15 / calcium alginate composite microspheres as a carrier to fix mannanase in an enzyme solution by adopting an embedding-covalent crosslinking method, so as to obtain the high-stability immobilized mannanase. The preparation method uses the PAMAM modified SBA-15 / calcium alginate composite microspheres as the carrier to fix the mannanase by adopting the embedding-covalent crosslinking synergistic method, so that the pH tolerance, the circulation stability and the hypoglycemic efficiency of the enzyme are improved, and the problems of the traditional immobilized enzyme, such as large enzyme activity loss, easy leakage and poor stability under high temperature, are solved.

To provide a tablet that is easy to swallow and also has reduced production cost, and a method of producing the same.SOLUTION: A tablet has a naked tablet containing a gelator, and at least one selected from sugar alcohol, monosaccharide, disaccharide, oligosaccharide, cellulose, cellulose derivative, starch, starch derivative and starch decomposition product. Preferably, the gelator is at least one selected from xanthan gum, locust bean gum, guar gum, mannan, glucomannan, hyaluronan, agar, alginic acid, tamarind gum, psyllium seed gum, tara gum, carrageenan, acacia gum, gum arabic, ghatti gum, tragacanth gum, karaya gum, cassia gum, rhamsan gum, welan gum, macrophomopsis gum, curdlan, pullulan, gellan gum, pectin, and soybean polysaccharide, gelatin, collagen, polyglutamic acid, polylactic acid, polyglutamic acid and the like.SELECTED DRAWING: None

The invention discloses a ferroptosis inducer based on fungal mannan and application of the ferroptosis inducer. Specifically, the invention provides an application of an active component, the active component is selected from Flo8 gene deletion type candida albicans sourced mannan (FM), or pharmaceutically acceptable salts thereof, or active derivatives thereof, the active component is used for preparing a preparation, a medicine or a composition, and the preparation, the medicine or the composition is used for inducing cell ferroptosis. Or the active component is used for preparing a ferroptosis inducer; or the active ingredients are used for preparing health-care products; or the active ingredient is used for preparing a medical device. The FM provided by the invention can activate SYK kinase to regulate and control TRIM25-mediated GPX4 ubiquitination degradation, and specifically induce tumor cell ferroptosis, thereby playing a role in inhibiting the occurrence and development of tumors.

[Problem] To provide a composition for regulating blood pressure for a healthy person. [Solution] A blood-pressure-regulating composition for a healthy person, said composition being characterized by containing a guar gum degradation product, and being characterized in that: 70 mass% or more of the guar gum degradation product has an average molecular weight within the average molecular weight range of 1.0 × 103 to 1.0 × 105; the composition has a viscosity of 10 mPa·s or less when a 2 mass% aqueous solution at 37°C is measured at 10 rpm using an E-type viscometer, or has a viscosity of 5 mPa·s or less when the aqueous solution is measured at 20 rpm, or has a viscosity of 3 mPa·s or less when the aqueous solution is measured at 30 rpm; the composition is obtained by hydrolyzing a galactomannan polysaccharide which contains guar-derived endosperm and in which the content ratio (galactose:mannose) of galactose and mannose is within the range of 1:1.3 to 1:2, by using a microorganism-derived β-mannanase to reduce the molecular weight of the polysaccharide; and the composition contains at least 70 mass% of dietary fiber in terms of the dietary fiber content stipulated in the enzyme-HPLC method.

The invention relates to a β-glucan-rich Saccharomyces cerevisiae yeast cell wall extract for use in the prevention or treatment of a disease associated with or caused by a Lawsonia intracellularis infection in pigs, characterised in that the extract comprises β-glucans and mannans, where the β-glucans are present in the form of a mixture of β-1,3-glucans and β-1,6-glucans in a total amount of greater than or equal to 50% by weight, notably of between 50% and 99% by weight, and where the mannans are present in a total amount less than 5% by weight, notably of between 1% and 5% by weight.

The invention provides a preparation method and application of a mirabilis jalapa extract, and belongs to the technical field of skin care products. The method comprises the following steps: (1) crushing mirabilis jalapa until the particle size is 100-300 microns, and then carrying out steam explosion treatment to obtain steam-exploded mirabilis jalapa; (2) mixing the steam-exploded mirabilis jalapa with water, adding a compound enzyme preparation, and performing enzymolysis treatment to obtain enzymatic hydrolysate; and (3) carrying out concentration and freeze-drying treatment on the enzymatic hydrolysate to obtain the mirabilis jalapa extract. According to the method, the mirabilis jalapa is subjected to steam explosion treatment and then subjected to enzymolysis treatment through mannase, cellulase and xylanase, so that effective components in the mirabilis jalapa can be fully extracted into enzymatic hydrolysate, and the extraction efficiency is guaranteed.

The utility model discloses an adjustable partition structure for mannan storage, which belongs to the technical field of mannan storage, and adopts the technical scheme that the adjustable partition structure comprises a box body, a plurality of adjusting components are movably connected in the box body, a plurality of partition components are arranged at the tops of the adjusting components, and each partition component comprises a movable upright post; the problems that an existing storage device is poor in separation effect, mannan cannot be stored according to different structures, mannan of different structures is possibly different in stability, solubility and the like due to the fact that the property of mannan is closely related to the structure of mannan to a certain degree, and mannan cannot be effectively separated, and the storage effect is poor are solved. The problems that in the prior art, due to the fact that the mannan can be mutually influenced in the storage process, for example, part of mannan is affected by damp or other impurities and deteriorates, chain reaction is possibly caused, the quality of the whole batch of mannan is affected, and the use convenience of the device is reduced are solved.

The present invention relates to the technical field of methods for preparing eutectic gels, and specifically discloses a method for rapidly initiating the polymerization of eutectic solvents to prepare eutectic gels, which specifically includes the following steps: Step 1, first, using industrial xylan, or cellulose, or glucomannan, or arabinoglucose, or mannan as raw materials, dialdehyde xylan (DAX) is prepared by the periodate oxidation method as follows: 20.0 g of industrial xylan is added to 800 mL of deionized water respectively, stirred until evenly dispersed to form a suspension, then 50.0 g of NaIO<subgt;4< / subgt; is weighed and added to the above suspension, and then stirred and reacted under dark at room temperature for different times. After the reaction is completed, 12 mL of ethylene glycol is slowly added to the reaction system to terminate the reaction; by using the dialdehyde xylan (DAX) solution to stabilize the LM nanodroplets, and using the DAX / LM dispersion to rapidly initiate the polymerization reaction of ChCl / AM in one step to prepare the DLPD eutectic gel, and no free radical initiator and crosslinking agent are required during the preparation process.

The invention discloses highly acetylated glucomannan and application thereof in preparation of a product with an effect of relieving prediabetes mellitus, and belongs to the technical field of medicines. In-vivo experiments prove that the glucomannan with high acetylation degree has the effect of relieving the prediabetic stage, which is specifically reflected in weight gain of mice in the prediabetic stage, regulation of blood glucose metabolism, improvement of glucose tolerance and insulin resistance, regulation of blood lipid metabolism, protection of liver and pancreatic tissues and reduction of epididymal fat cell size. The invention provides an important basis for developing a dietary formula suitable for prediabetic patients, and provides a new method for prevention and management of diabetes mellitus.

The present application relates to the technical field of genetic engineering and protein engineering, and particularly provides a mannanase mutant and application thereof.The mutant is obtained by mutating the 175th amino acid of mannanase with the amino acid sequence of SEQ ID NO:4 from Ser to Thr, and the specific activity of the mutant is significantly higher than that of the wild type, so that the mutant can be widely applied to the production of livestock and poultry feed and marine aquaculture feed.

This invention discloses a composition that can effectively soothe and repair sensitive skin, its preparation method, and its application, relating to the field of skincare products. The composition of this invention, by weight, comprises 5-18 parts β-glucan, 1-10 parts mannan, 8-15 parts yeast polypeptides, 1-10 parts sodium hyaluronate, 2-5 parts magnesium ascorbate phosphate, and 8-15 parts Scutellaria baicalensis root extract. This composition is mild and non-irritating, can quickly and effectively relieve skin sensitivity reactions, protect the skin barrier, and has good storage stability, not easily affected by environmental factors such as temperature and oxygen.

A mannanase at least 75% identical to SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4, a poly-nucleotide encoding mannanase, an expression construct comprising the polynucleotide, and a host cell comprising the polynucleotide or the expression construct.

The invention discloses cold shock induced autolytic saccharomyces cerevisiae as well as a construction method and application thereof. The cold shock induced autolytic saccharomyces cerevisiae expresses a gene for coding and decomposing a cell wall component, and the gene for coding and decomposing the cell wall component comprises a coding gene bgl2 of incision beta-1, 3-glucanase, a coding gene cts1 of chitinase and a coding gene manA of beta-mannase; the promoter for coding the gene for decomposing the cell wall component is a cold shock inducible promoter. According to the prepared cold shock induced autolysis saccharomyces cerevisiae, engineering bacteria can be induced to generate obvious autolysis through one-time cold shock, meanwhile, reaction products do not need to be sterilized at high temperature, and the browning phenomenon caused by the Maillard reaction of polysaccharide and protein in filtrate under the high-temperature condition is avoided.

This invention belongs to the field of agricultural fertilizer technology, specifically relating to an organic water-soluble fertilizer based on molasses fermentation concentrate and its preparation method. The organic water-soluble fertilizer comprises molasses fermentation concentrate, a compound enzyme preparation, polyaspartic acid, EDTA-2Na, and water-soluble nitrogen, phosphorus, and potassium fertilizer. It employs a staged temperature-varying enzymatic hydrolysis process. Laccase first oxidizes and degrades polyphenols at 30–35°C, opening the polyphenol-polysaccharide complex structure. Then, the temperature is raised to 42–48°C, where β-glucanase, xylanase, and mannanase directionally degrade colloidal polysaccharides. Simultaneously, EDTA-2Na is introduced to chelate metal ions, and polyaspartic acid inhibits scale dispersion. These three components synergistically form an "enzymatic hydrolysis-chelation-scale inhibition" anti-clogging system. This invention addresses the technical problems of existing molasses fermentation concentrate fertilizers being prone to clogging in drip irrigation systems, having low efficiency in constant-temperature synchronous enzymatic hydrolysis, and having an imperfect single anti-clogging mechanism. It provides an organic water-soluble fertilizer composed of molasses fermentation concentrate, a compound enzyme preparation, polyaspartic acid, EDTA-2Na, and water-soluble nitrogen, phosphorus, and potassium fertilizer. This invention effectively solves the problem of clogging of honey fermentation concentrate in drip irrigation systems, improves enzymatic hydrolysis efficiency, and is suitable for drip irrigation fertilization of various crops such as bananas and vegetables.

The present invention relates to newly idenified GH26 mannanases and their use as enhancers of enzyme benefits in detergents as well as a detergent composition comprising said mannanases.

The present invention relates to a compound drug for preventing and treating porcine reproductive and respiratory syndrome (PRRS), belonging to the field of veterinary drugs. The present invention makes an oral pharmaceutical preparation by mixing an animal-specific macrolide drug, sodium houttuyfonate, mannan oligosaccharide peptide and pharmaceutical excipients in a certain proportion. The drug of the present invention can effectively treat acute-phase PRRS, rapidly relieve the clinical symptoms of diseased pigs and improve the survival rate.

The present invention relates to the technical field of biology, and in particular to a β-mannanase mutant M-Q7S having a high enzyme activity, a recombinant strain, and a use of the mutant. The single-site β-mannanase mutant Csman5A-Q7S is obtained by mutating into serine (S) the amino acid asparagine (Q) at position 7 of the β-mannanase having the amino acid sequence as shown in SEQ ID NO: 1. Experiments show that the specific enzyme activity of the mutant Csman5A-Q7S in the whole induction period is significantly greater than that of the original Csman5A, and after 144 h of induction, when the specific enzyme activity reaches the maximum value, the specific enzyme activity of the mutant Csman5A-Q7S is 5.4 times that of the original Csman5A.

Disclosed herein are mannan nanogels as a novel vaccine delivery platform as well as a novel method of making a self-assembling mannan nanogel for in vivo delivery of therapeutic agents.

The present invention provides a functional paper product which has water resistance, oil resistance and can be recycled. A functional paper product (1) according to the present invention comprises a base paper (20) and a coating film (10) formed on the base paper (20), the coating film (10) having, as a main component, modified mannan in which acetyl groups in konjac mannan are free, the coating film (10) being obtained by curing a swollen modified mannan sol in a state in which the swollen modified mannan sol is immersed in gaps between cellulose fibers of the base paper (20), and the viscosity of the swollen modified mannan before curing is 3000 mPa * s or less.